Turkiye Klinikleri Journal of Medical Sciences

.: ORIGINAL RESEARCH
Berberin-Klorürün Meme Kanseri Hücreleri Üzerindeki Sitotoksik Etkilerinin Değerlendirilmesi ve Antimikrobiyal Aktivite Analizi
Evaluation of Cytotoxic Effects of Berberine-Chloride in Breast Cancer Cells and Antimicrobial Activity Analysis
Ergül Mutlu ALTUNDAĞa, Eda BECERb,c Gizem ŞANLITÜRKd,e, Mümtaz GÜRANd, H. Seda VATANSEVERc,f
aDoğu Akdeniz Üniversitesi Dr. Fazıl Küçük Tıp Fakültesi, Tıbbi Biyokimya ABD, Gazimağusa, KKTC
bYakın Doğu Üniversitesi Eczacılık Fakültesi, Biyokimya ABD, Lefkoşa, KKTC
cYakın Doğu Üniversitesi DESAM Enstitüsü, Lefkoşa, KKTC
dDoğu Akdeniz Üniversitesi Dr. Fazıl Küçük Tıp Fakültesi, Tıbbi Mikrobiyoloji ABD, Gazimağusa, KKTC
eDoğu Akdeniz Üniversitesi Fen-Edebiyat Fakültesi, Kimya ABD, Gazimağusa, KKTC
fManisa Celal Bayar Üniversitesi Tıp Fakültesi, Histoloji ve Embriyoloji ABD, Manisa, TÜRKİYE
Turkiye Klinikleri J Med Sci. 2020;40(3):342-8
doi: 10.5336/medsci.2020-74815
Article Language: TR
Full Text
ÖZET
Amaç: Bu çalışmada, berberin-klorürün antikanser etkinliğinin, 2 farklı kanser hücre hattında (MCF-7 meme kanseri hücreleri ve M4A4 metastatik meme kanseri hücreleri) analiz edilmesi ve antibakteriyel etkinliğinin 5 farklı standart bakteri suşunda araştırılması amaçlanmıştır. Gereç ve Yöntemler: Çalışmada, MCF-7 meme kanseri hücreleri ve M4A4 metastatik meme kanseri hücreleri olmak üzere 2 hücre hattına karşı MTT analizi uygulanarak, berberin-klorürün zamana bağlı oluşturduğu inhibisyon araştırılmıştır. Ayrıca berberin-klorürün 6 standart suş [Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, 'methicillin resistant S. aureus (MRSA)', Pseudomonas aeruginosa ve Enterococcus faecalis) kullanılarak antibakteriyel etkisi broth mikrodilüsyon ve agar zon difüzyon yöntemleri ile analiz edilmiştir. Bulgular: MCF-7 hücreleri için hücre canlılığının %50 inhibe olduğu konsantrasyon, 72 saatlik berberin-klorür muamelesi sonrası 19,57 µM, M4A4 hücreleri için ise 77,7 µM olarak bulunmuştur. Broth mikrodilüsyon testinde minimum inhibitör konsantrasyonu değerleri, S. aureus, MRSA, E. coli, K. pneumoniae, P. aeruginosa ve E. faecalis için sırasıyla 0,49 µg/mL, 0,98 µg/mL, 0,0038 µg/mL, 3,91 µg/mL, 0,03 µg/mL ve 0,49 µg/mL olarak bulunmuştur. Agar kuyucuk difüzyon testinde zon inhibisyon değerleri S. aureus, MRSA, E. coli, K. pneumoniae, P. aeruginosa ve E. faecalis için sırasıyla 30 mm, 30 mm, 35 mm, 17 mm, 33 mm ve 20 mm olarak bulunmuştur. Sonuç: Çalışmada, berberinklorürün farklı hücre hatlarına antikanser etkisi ve yaygın olarak enfeksiyona sebep olan bakterilere karşı antibakteriyel etkinliği olduğu in vitro olarak gösterilmiştir.

Anahtar Kelimeler: Berberin-klorür; antibakteriyel; antikanser; sitotoksisite; MTT analizi
ABSTRACT
Objective: In this study, it was aimed to analyse the anti-cancer activity of berberine-chloride in two different cancer cell lines (MCF-7 breast cancer cells and M4A4 metastatic breast cancer cells) and to investigate the antibacterial activity in five different standard bacterial strains. Material and Methods: In the study, the timedependent inhibition by berberine chloride was investigated by applying MTT assay against two cell lines, which are MCF-7 breast cancer cells and M4A4 metastatic breast cancer cells. In addition, the anti-bacterial effect of berberine chloride was analysed by using six standard strains [Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, methicillin resistant S. aureus (MRSA), Pseudomonas aeruginosa and Enterococcus faecalis] with the broth microdilution and agar zone diffusion methods. Results: The concentration at which cell viability was 50% inhibited for MCF-7 cells after 72 hours of berberine chloride treatment was found to be 19.57 µM and 77.7 µM for M4A4 cells. Minimum inhibitory concentration values in broth microdilution test for S. aureus, MRSA, E. coli, K. pneumoniae, P. aeruginosa and E. faecalis, was found to be 0.49 µg/mL, 0.98 µg/mL, 0.0038 µg/mL 3.91 µg/mL, 0.03 µg/mL and 0.49 µg/mL respectively. Zone inhibition values in agar well diffusion test was found as 30 mm, 30 mm, 35 mm, 17 mm, 33 mm and 20 mm for S. aureus, MRSA, E. coli, K. pneumoniae, P. aeruginosa and E. faecalis, respectively. Conclusion: In the study, berberine-chloride anti-cancer effect on different cell lines and antibacterial activity against commonly infectious bacteria has been shown in-vitro.

Keywords: Berberine chloride; anti-bacterial; anti-cancer; cytotoxicity; MTT assay
REFERENCES:
  1. Toriola AT, Colditz GA. Trends in breast cancer incidence and mortality in the United States: implications for prevention. Breast Cancer Res Treat. 2013;138(3):665-73. [Crossref]  [PubMed] 
  2. Tan W, Li Y, Chen M, Wang Y. Berberine hydrochloride: anticancer activity and nanoparticulate delivery system. Int J Nanomedicine. 2011;6:1773-7. [Crossref]  [PubMed]  [PMC] 
  3. Affuso F, Mercurio V, Fazio V, Fazio S. Cardiovascular and metabolic effects of berberine. World J Cardiol. 2010;2(4):71-7. [Crossref]  [PubMed]  [PMC] 
  4. Wang X, Feng S, Ding N, He Y, Li C, Li M, et al. Anti-inflammatory effects of berberine hydrochloride in an LPS-induced murine model of mastitis. Evid Based Complement Alternat Med. 2018;2018:5164314. [Crossref]  [PubMed]  [PMC] 
  5. Pirillo A, Catapano AL. Berberine, a plant alkaloid with lipid- and glucose-lowering properties: from in vitro evidence to clinical studies. Atherosclerosis. 2015;243(2):449-61. [Crossref]  [PubMed] 
  6. Zhang H, Wei J, Xue R, Wu JD, Zhao W, Wang ZZ, et al. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism. 2010;59(2):285-92. [Crossref]  [PubMed] 
  7. Li X, Zhao SJ, Shi HL, Qiu SP, Xie JQ, Wu H, et al. Berberine hydrochloride IL-8 dependently inhibits invasion and IL-8-independently promotes cell apoptosis in MDA-MB-231 cells. Oncol Rep. 2014;32(6):2777-88. [Crossref]  [PubMed] 
  8. Chen C, Yu Z, Li Y, Fichna J, Storr M. Effects of berberine in the gastrointestinal tract-a review of actions and therapeutic implications. Am J Chin Med. 2014;42(5):1053-70. [Crossref]  [PubMed] 
  9. Hu Q, Li L, Zou X, Xu L, Yi P. Berberine attenuated proliferation, invasion and migration by targeting the AMPK/HNF4α/WNT5A pathway in gastric carcinoma. Front Pharmacol. 2018;9:1150. [Crossref]  [PubMed]  [PMC] 
  10. Liu H, Huang C, Wu L, Wen B. Effect of evodiamine and berberine on miR-429 as an oncogene in human colorectal cancer. Onco Targets Ther. 2016;9:4121-7. [Crossref]  [PubMed]  [PMC] 
  11. Tian Y, Zhao L, Wang Y, Zhang H, Xu D, Zhao X, et al. Berberine inhibits androgen synthesis by interaction with aldo-keto reductase 1C3 in 22Rv1 prostate cancer cells. Asian J Androl. 2016;18(4):607-12. [Crossref]  [PubMed]  [PMC] 
  12. Sun Y, Wang W, Tong Y. Berberine inhibits proliferative ability of breast cancer cells by reducing metadherin. Med Sci Monit. 2019;25: 9058-66. [Crossref]  [PubMed]  [PMC] 
  13. Li J, Liu F, Jiang S, Liu J, Chen X, Zhang S, et al. Berberine hydrochloride inhibits cell proliferation and promotes apoptosis of non-small cell lung cancer via the suppression of the MMP2 and Bcl-2/Bax signaling pathways. Oncol Lett. 2018;15(5):7409-14. [Crossref] 
  14. Patil JB, Kim J, Jayaprakasha GK. Berberine induces apoptosis in breast cancer cells (MCF-7) through mitochondrial-dependent pathway. Eur J Pharmacol. 2010;645(1-3):70-8. [Crossref]  [PubMed] 
  15. Barry AL, Craig WA, Nadler H, Reller LB, Sanders CC, Swenson JM. M26-A Methods for determining bactericidal activity of antimicrobial agents; approved guideline. National Committee for Clinical Laboratory Standards. 1999;19(18):1-29. http://demo.nextlab.ir/getattachment/096a51d4-1530-4f81-92c0-f5477c584b9b/CLSI-M26-A.aspx
  16. Imenshahidi M, Hosseinzadeh H. Berberine and barberry (Berberis vulgaris): a clinical review. Phytother Res. 2019;33(3):504-23. [Crossref]  [PubMed] 
  17. Xiao D, Liu Z, Zhang S, Zhou M, He F, Zou M, et al. Berberine derivatives with different pharmacological activities via structural modifications. Mini Rev Med Chem. 2018;18(17): 1424-41. [Crossref]  [PubMed] 
  18. Wang K, Feng X, Chai L, Cao S, Qiu F. The metabolism of berberine and its contribution to the pharmacological effects. Drug Metab Rev. 2017;49(2):139-57. [Crossref]  [PubMed] 
  19. Tan W, Zhong Z, Wang S, Suo Z, Yang X, Hu X, et al. Berberine regulated lipid metabolism in the presence of C75, compound C, and TOFA in breast cancer cell line MCF-7. Evid Based Complement Alternat Med. 2015;2015:396035. [Crossref]  [PubMed]  [PMC] 
  20. Guamán Ortiz LM, Croce AL, Aredia F, Sapienza S, Fiorillo G, Syeda TM, et al. Effect of new berberine derivatives on colon cancer cells. Acta Biochim Biophys Sin (Shanghai). 2015;47(10):824-33. [Crossref]  [PubMed] 
  21. Chen Q, Qin R, Fang Y, Li H. Berberine sensitizes human ovarian cancer cells to cisplatin through miR-93/PTEN/Akt signaling pathway. Cell Physiol Biochem. 2015;36(3):956-65. [Crossref]  [PubMed] 
  22. Liu D, Meng X, Wu D, Qiu Z, Luo H. A natural isoquinoline alkaloid with antitumor activity: studies of the biological activities of berberine. Front Pharmacol. 2019;10:9. [Crossref]  [PubMed]  [PMC] 
  23. Hussein SAM, Barakat HH, Merfort I, Nawwar MAM. Tannins from the leaves of Punica granatum. Phytochemistry. 1997;45(4):819-23. [Crossref] 
  24. Cushnie TPT, Lamb AJ. Antimicrobial activity of flavonoids. Int J Antimicrob Agents. 2005;26(5):343-56. [Crossref]  [PubMed]  [PMC] 
  25. Zuo GY, Li Y, Han J, Wang GC, Zhang YL, Bian ZQ. Antibacterial and synergy of berberines with antibacterial agents against clinical multi-drug resistant isolates of methicillin-resistant Staphylococcus aureus (MRSA). Molecules. 2012;17(9):10322-30. [Crossref]  [PubMed]  [PMC] 
  26. Hong SB, Rhee MH, Yun BS, Lim YH, Song HG, Shin KS. Synergistic anti-bacterial effects of phellinus baumii ethyl acetate extracts and β-lactam antimicrobial agents against methicillin-resistant Staphylococcus aureus. Ann Lab Med. 2016;36(2):111-6. [Crossref]  [PubMed]  [PMC] 
  27. Du GF, Le YJ, Sun X, Yang XY, He QY. Proteomic investigation into the action mechanism of berberine against Streptococcus pyogenes. J Proteomics. 2020;215:103666. [Crossref]  [PubMed] 
  28. Adamczak A, Ożarowski M, Karpiński TM. Antibacterial activity of some flavonoids and organic acids widely distributed in plants. J Clin Med. 2019;9(1):109. [Crossref]  [PubMed]  [PMC] 
  29. Tan J, Wang J, Yang C, Zhu C, Guo G, Tang J, et al. Antimicrobial characteristics of berberine against prosthetic joint infection-related Staphylococcus aureus of different multi-locus sequence types. BMC Complement Altern Med. 2019;19(1):218. [Crossref]  [PubMed]  [PMC] 
  30. Pierpaoli E, Cirioni O, Simonetti O, Orlando F, Giacometti A, Lombardi P, et al. Potential application of berberine in the treatment of Escherichia coli sepsis. Nat Prod Res. 2020;1-6. [Crossref]  [PubMed] 
  31. Shi C, Li M, Muhammad I, Ma X, Chang Y, Li R, et al. Combination of berberine and ciprofloxacin reduces multi-resistant Salmonella strain biofilm formation by depressing mRNA expressions of luxS, rpoE, and ompR. J Vet Sci. 2018;19(6):808-16. [Crossref]  [PubMed]  [PMC] 
  32. Xu Y, Quan H, Wang Y, Zhong H, Sun J, Xu J, et al. Requirement for ergosterol in berberine tolerance underlies synergism of fluconazole and berberine against fluconazole-resistant Candida albicans isolates. Front Cell Infect Microbiol. 2017;7:491. [Crossref]  [PubMed]  [PMC] 

.: Up To Date

Login



Contact


Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com